1
Conclusions: Patients with Huntington's disease and psychotic symptoms may have a familial predisposition to develop psychosis.
2
However, it is not currently possible to predict which ARMS individuals will develop psychosis from clinical assessment alone.
3
These results are consistent with other findings pointing to early developmental deficits in patients who subsequently develop psychosis.
4
The use of antipsychotics in this population is not supported, because most individuals with ARMS are unlikely to develop psychosis.
5
About 25 to 50 percent of Alzheimer's patients may develop psychosis, including hallucinations and delusions.
6
Comparison of ARMS subjects who do, and do not, develop psychosis can reveal which factors are critical for the onset of illness.
7
New research shows that smoking can triple the chances of developing psychosis.
8
Scientific research has suggested smoking cannabis can double the risk of developing psychosis.
9
Only one person not meeting UHR criteria developed psychosis in the follow up period.
10
The prevalence of previous trauma in people at UHR of developing psychosis is high.
11
Context: Identification of individuals at high risk of developing psychosis has relied on prodromal symptomatology.
12
Volume loss in the individuals who developed psychosis could not be attributed to medication use.
13
The CHR syndrome is specific as a marker for research on predictors and mechanisms of developing psychosis.
14
Background: Treatment of those at clinical high-risk (CHR) for developing psychosis may lead to preventive strategies.
15
Here we compared cross-sectional and longitudinal structural neuroimaging studies distinguishing high-risk subjects developing psychosis from those who did not.
16
Cannabis use is associated with 2-4 times the likelihood of developing psychosis in healthy individuals.